Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | QDPR | P09417 | 3/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1961556 | 0.99 | HTR2C (0.58) | HTR2CSIGMAR1QDPRPDE3BPDE3A | |
| SCHEMBL3382904 | 0.84 | HTR2C (0.58) | HTR2CSIGMAR1QDPRPDE3BPDE3A | |
| SCHEMBL3385014 | 0.81 | SIGMAR1 (0.68) | HTR2CSIGMAR1QDPR | |
| SCHEMBL5541715 | 0.81 | HTR2C (0.58) | HTR2CSIGMAR1QDPRPDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL2158640 | 0.80 | HTR2C (0.69) | HTR2CSIGMAR1QDPR | |
| SCHEMBL6586606 | 0.79 | HTR2C (0.60) | HTR2CSIGMAR1QDPRPDE3BPDE3A | |
| SCHEMBL2269930 | 0.77 | SIGMAR1 (0.67) | HTR2CSIGMAR1QDPR | |
| SCHEMBL1472528 | 0.76 | HTR2C (0.69) | HTR2CSIGMAR1QDPRP2RY14 | |
| SCHEMBL4698302 | 0.76 | HTR2C (0.50) | HTR2CSIGMAR1QDPRPDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL16423171 | 0.76 | HTR2C (0.68) | HTR2CSIGMAR1QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102124001-B | 2-OXOALKYL-1-PIPERAZIN-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS | 2014-01-22 | — | — | CN | disclosed |
| WO-2011144835-A3 | TUBULAR PHOTOVOLTAIC DEVICE FOR PRODUCING ELECTRICAL ENERGY | THEROND PATRICK (FR) | 2012-05-10 | — | — | WO | disclosed |
| EP-2297148-B1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-01-04 | — | — | EP | disclosed |
| EP-2310383-B1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2011-11-30 | — | — | EP | disclosed |
| CN-102124001-A | 2-OXOALKYL-1-PIPERAZIN-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS | 2011-07-13 | — | — | CN | disclosed |
| EP-1963268-B1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080269286-A1 | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-10-30 | — | — | US | disclosed |
| EP-1963268-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | Neurosearch Sweden AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007065655-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269286-A1 | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission | SLC6A2, SLC18A2, PNMT | HTR2C 19/4885SIGMAR1 307/4885QDPR 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.